TLX News: ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability - 19th Oct 2023, 9:01am

[annb0t]

The study has achieved its primary objectives, confirming the safety and tolerability profile of TLX591 administered in two doses, two weeks apart in combination with standard of care (SoC) Preliminary activity demonstrates meaningful PSA[1] reduction; monitoring of patients is ongoing, including for rPFS[2] Findings reinforce the potential advantages of this first-in-class radio-antibody drug conjugate (rADC) investigational therapy, consistent with previous clinical studies of TLX591[3]

ME...

>>> Read more: ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability